Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder : A genome-wide analysis of individual-level data and a meta-analysis (CROSBI ID 202933)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Tansey, Katherine E. ; Guipponi, Michel ; Perroud, Nader ; Bondolfi, Guido ; Domenici, Enrico ; Evans, David ; Hall, Stephanie K. ; Hauser, Joanna ; Henigsberg, Neven ; Hu, Xiaolan et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder : A genome-wide analysis of individual-level data and a meta-analysis // PLoS medicine, 9 (2013), 10; e1001326, 10. doi: 10.1371/journal.pmed.1001326

Podaci o odgovornosti

Tansey, Katherine E. ; Guipponi, Michel ; Perroud, Nader ; Bondolfi, Guido ; Domenici, Enrico ; Evans, David ; Hall, Stephanie K. ; Hauser, Joanna ; Henigsberg, Neven ; Hu, Xiaolan ; Jerman, Borut ; Maier, Wolfgang ; Mors, Ole ; O'Donovan, Michael ; Peters, Tim J. ; Placentino, Anna ; Rietschel, Marcella ; Souery, Daniel ; Aitchison, Katherine J. ; Craig, Ian ; Farmer, Anne ; Wendland, Jens R. ; Malafosse, Alain ; Holmans, Peter ; Lewis, Glyn ; Lewis, Cathryn M. ; Stensbøl, Tine Bryan ; Kapur, Shitij ; McGuffin, Peter ; Uher, Rudolf

engleski

Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder : A genome-wide analysis of individual-level data and a meta-analysis

It has been suggested that outcomes of antidepressant treatment for major depressive disorder could be significantly improved if treatment choice is informed by genetic data. This study aims to test the hypothesis that common genetic variants can predict response to antidepressants in a clinically meaningful way. The NEWMEDS consortium, an academia- industry partnership, assembled a database of over 2, 000 European-ancestry individuals with major depressive disorder, prospectively measured treatment outcomes with serotonin reuptake inhibiting or noradrenaline reuptake inhibiting antidepressants and available genetic samples from five studies (three randomized controlled trials, one part-randomized controlled trial, and one treatment cohort study). After quality control, a dataset of 1, 790 individuals with high-quality genome-wide genotyping provided adequate power to test the hypotheses that antidepressant response or a clinically significant differential response to the two classes of antidepressants could be predicted from a single common genetic polymorphism. None of the more than half million genetic markers significantly predicted response to antidepressants overall, serotonin reuptake inhibitors, or noradrenaline reuptake inhibitors, or differential response to the two types of antidepressants (genome-wide significance p<5×10(-8)). No biological pathways were significantly overrepresented in the results. No significant associations (genome-wide significance p<5×10(-8)) were detected in a meta-analysis of NEWMEDS and another large sample (STAR*D), with 2, 897 individuals in total. Polygenic scoring found no convergence among multiple associations in NEWMEDS and STAR*D. No single common genetic variant was associated with antidepressant response at a clinically relevant level in a European-ancestry cohort. Effects specific to particular antidepressant drugs could not be investigated in the current study.

genetic predictors ; response to serotonergic and noradrenergic antidepressants ; major depressive disorder

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

9 (10)

2013.

e1001326

10

objavljeno

1549-1277

1549-1676

10.1371/journal.pmed.1001326

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost